Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
2281results about How to "Reduce expression" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Use of chimeric nucleases to stimulate gene targeting
ActiveUS20050026157A1Ameliorate genetic disorderIncrease productionAntibacterial agentsFusion with DNA-binding domainGene targetsGenetic Change
Gene targeting is a technique to introduce genetic change into one or more specific locations in the genome of a cell. For example, gene targeting can introduce genetic change by modifying, repairing, attenuating or inactivating a target gene or other chromosomal DNA. In one aspect, this disclosure relates to methods and compositions for gene targeting with high efficiency in a cell. This disclosure also relates to methods of treating or preventing a genetic disease in an individual in need thereof. Further disclosed are chimeric nucleases and vectors encoding chimeric nucleases.
Owner:CALIFORNIA INST OF TECH
Methods and compositions for therapeutic use of RNA interference
InactiveUS20030157030A1Effective amountImprove angiogenesisOrganic active ingredientsPowder deliveryGene expressionSmall interfering RNA
Abstract of Disclosure The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an amount sufficient to attenuate expression of a target gene by an RNA interference mechanism, e.g., in a sequence-dependent, PKR-independent manner. In particular, the subject method can be used to alter the growth, survival or differentiation of cells for therapeutic and cosmetic purposes.
Owner:INSERT THERAPEUTICS INC
RNA interference for the treatment of heart failure
InactiveUS8404658B2Reduce expressionDecreasing ventricular arrhythmiasOrganic active ingredientsTissue culturePhospholambanTransfection
The present invention relates to targeted RNAi for the treatment of heart failure by modulating defective cardiac Ca2+ homeostasis via decreasing expression or activity of phospholamban (PLB) using adeno-associated virus (AAV) transfection of cardiomyocytes. Methods for decreasing ventricular arrhythmias, as well as methods for overall improvement of survival from heart failure in subjects are also disclosed. Further, the present invention provides methods which can be used to diagnose susceptibility to treatment by RNAi, and includes pharmaceutical compositions, kits and vectors including an RNAi sequence.
Owner:NANOCOR THERAPEUTICS +1
Lipids, lipid compositions, and methods of using them
InactiveUS20110200582A1Reducing and inhibiting and ameliorating diseaseLower Level RequirementsBiocideOrganic active ingredientsLipidomeActive agent
Owner:NOVARTIS AG
Methods and compositions for the treatment of persistent infections
ActiveUS20070122378A1Reduced activityReduce expressionAntibacterial agentsOrganic active ingredientsMicrobiologyPathology
The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
Owner:DANA FARBER CANCER INST INC +3
Compositions and methods for the delivery of nucleic acids
InactiveUS20110117125A1Reduce particle aggregationReduce selection requirementsAntibacterial agentsOrganic active ingredientsLipid particleProtein target
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
Owner:THE UNIV OF BRITISH COLUMBIA +2
Regulation of BCL-2 gene expression
InactiveUS7022831B1High sensitivityIncreased chemosensitivitySugar derivativesPeptide/protein ingredientsOligomerCancer cell
Owner:UCB SA
Innate immune suppression enables repeated delivery of long RNA molecules
InactiveUS20100273220A1Suppressing innate immune responseReduce expressionSugar derivativesArtificial cell constructsENCODETransient transfection
The present invention relates in part to methods for suppressing the innate immune response of a cell to transfection with an exogenous nucleic acid, to methods for increasing expression of a protein encoded by an exogenous nucleic acid by repeated delivery of the exogenous nucleic acid to a cell, and to methods of changing the phenotype of a cell by differentiating, transdifferentiating or dedifferentiating cells by repeatedly delivering one or more nucleic acids that encode defined proteins. A method is provided for extended transient transfection by repeated delivery of an in vitro-transcribed RNA (“ivT-RNA”) to a cell to achieve a high and sustained level of expression of a protein encoded by an ivT-RNA transcripts.
Owner:MASSACHUSETTS INST OF TECH
Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
The present invention provides design and synthesis of oligomeric compounds and compositions that can be administered to reduce the activity of SARS virus in vivo or in vitro, to prevent or treat SARS virus-associated disease, to detect AARS virus, and to diagnose SARS virus-associated diseases.
Owner:IONIS PHARMA INC
Antisense modulation of bcl-x expression
InactiveUS7148204B2Promote apoptosisReduce expressionBiocideHeavy metal active ingredientsDiseaseSensitized cell
Compositions and methods are provided for modulating the expression of bcl-x. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bcl-x are preferred. Methods of using these compounds for modulation of bcl-x expression and for treatment of diseases associated with expression of bcl-x are also provided. Methods of sensitizing cells to apoptotic stimuli are also provided.
Owner:IONIS PHARMA INC
Modifying nicotine and nitrosamine levels in tobacco
InactiveUS6907887B2Lowering carcinogenic potentialReduce the amount requiredNervous disorderTobacco treatmentTobacco-specific nitrosaminesNicotiana tabacum
The present invention generally relates to tobacco and tobacco products having a reduced amount of nicotine and / or tobacco specific nitrosamines (TSNA). More specifically, several ways to make tobacco plants that have reduced nicotine and TSNA levels have been discovered. Embodiments include tobacco harvested from said tobacco plants, cured tobacco from said tobacco plants, tobacco products made with said cured tobacco and methods of making these compositions.
Owner:NORTH CAROLINA STATE UNIV
Activin-ActRIIa antagonists and uses for promoting bone growth
ActiveUS20070249022A1Increase in mineralizationReduce expressionPeptide/protein ingredientsAntibody mimetics/scaffoldsCancer researchAntagonist
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
Owner:ACCELERON PHARMA INC
Vault agents for chronic kidney disease
InactiveUS20120003201A1Reduce expressionConnective tissue peptidesTripeptide ingredientsAdhesion processRGD peptide
Owner:RGT UNIV OF CALIFORNIA
Recombinant IL-9 antibodies and uses thereof
InactiveUS20050002934A1Reduces function and activity and expressionReduced activityAntibacterial agentsNervous disorderAutoimmune diseaseImmunologic specificity
The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and / or ameliorating diseases and disorders associated with aberrant expression and / or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.
Owner:MEDIMMUNE LLC
Nucleic acid constructs and methods for producing altered seed oil compositions
InactiveUS20060206963A1Increased oleic acid contentReduce saturated fatty acid contentTransferasesBiofuelsFatty acid biosynthesisAdemetionine
The present invention is in the field of plant genetics and provides recombinant nucleic acid molecules, constructs, and other agents associated with the coordinate manipulation of multiple genes in the fatty acid synthesis pathway. In particular, the agents of the present invention are associated with the simultaneous enhanced expression of certain genes in the fatty acid synthesis pathway and suppressed expression of certain other genes in the same pathway. Also provided are plants incorporating such agents, and in particular plants incorporating such constructs where the plants exhibit altered seed oil compositions.
Owner:MONSANTO TECH LLC
Activin-ActRII antagonists and uses for increasing red blood cell levels
ActiveUS20090047281A1Easy to produceReduce expressionCompound screeningApoptosis detectionPrimateRed Cell
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Targets for controlling cellular growth and for diagnostic methods
InactiveUS20050003390A1Reduce expressionReduced activity of targetMicrobiological testing/measurementMaterial analysisAbnormal tissue growthApoptosis
A method of identifying a compound that induces apoptosis is disclosed. The method includes identifying compounds that inhibit the expression and / or activity of a target. Also disclosed are methods for inducing apoptosis by inhibiting one of the targets. The invention further includes methods for the diagnosis of a tumor that include determining the level of at least one of the targets as a biomarker in a patient sample, the level of the biomarker being indicative of the presence of tumor cells.
Owner:SURROMED
CHEMICALLY MODIFIED POLYCATION POLYMER FOR siRNA DELIVERY
InactiveUS20070231392A1Reduced gene expressionReduce expressionPowder deliverySpecial deliveryIonic polymerizationIn vivo
The present invention provides a unique non-viral carrier for nucleic acid delivery in vitro and in vivo, and methods of using thereof.
Owner:ABBOTT LAB INC
Compositions and methods for treatment of ear disorders
ActiveUS20110142917A1Reduces and inhibits expression of geneReduce expressionHeavy metal active ingredientsOrganic active ingredientsDiseasePresbycusis
The present invention relates to pharmaceutical compositions useful for topical, non-invasive delivery of an oligonucleotide to the ear and to methods for the treatment of an ear disorder, including hearing loss arising from chemical-induced ototoxicity, acoustic trauma and presbycusis; and microbial infections. The method comprises topically administering to the ear of a subject in need thereof a pharmaceutical composition comprising an inhibitory oligonucleotide, a permeability enhancer and a pharmaceutically acceptable carrier, wherein the oligonucleotide reduces or inhibits expression of a gene associated with the ear disorder in the subject.
Owner:QUARK FARMACUITIKALS INC
Device and method for treatment of wounds with nitric oxide
InactiveUS7122018B2Promote wound healingReduce the burden onBiocideOther blood circulation devicesHigh concentrationNitric oxide gas
Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing and preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used to reduce the microbial infection, manage exudates secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from 160–400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation, and increases collagenase expression to debride necrotic tissue at the wound site. After a first treatment period, a second treatment period at a lower concentration of nitric oxide, preferably ranging from 5–20 ppm may be used to restore the balance of nitric oxide and induce collagen expression aiding in the wound closure.
Owner:SENSORMEDICS +1
Antibody compositions and methods
InactiveUS20070065440A1High affinitySmall sizeAntibacterial agentsSenses disorderHigh concentrationVariable domain
Provided are concentrated preparations comprising single immunoglobulin variable domain polypeptides that bind target antigen with high affinity and are soluble at high concentration, without aggregation or precipitation, providing, for example, for increased storage stability and the ability to administer higher therapeutic doses.
Owner:DORMANTIS LTD
CHEMICALLY MODIFIED POLYCATION POLYMER FOR siRNA DELIVERY
InactiveUS20080112916A1Reduced gene expressionReduce expressionOrganic active ingredientsSpecial deliveryIn vivoViral vector
The present invention provides a unique non-viral carrier for nucleic acid delivery in vitro and in vivo, and methods of using thereof.
Owner:WAGNER ERNST +3
Activin-actriia antagonists and uses for promoting bone growth in cancer patients
ActiveUS20090142333A1Promote growthStimulates of mineralizationPeptide/protein ingredientsAntibody mimetics/scaffoldsIncreased Bone DensityBone growth
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
Owner:ACCELERON PHARMA INC
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
ActiveUS20080269070A1High yieldQuality improvementBacteriaMicrobiological testing/measurementHeterologousADAMTS Proteins
The present invention provides an array for rapidly identifying a host cell population capable of producing heterologous protein with improved yield and / or quality. The array comprises one or more host cell populations that have been genetically modified to increase the expression of one or more target genes involved in protein production, decrease the expression of one or more target genes involved in protein degradation, or both. One or more of the strains in the array may express the heterologous protein of interest in a periplasm compartment, or may secrete the heterologous protein extracellularly through an outer cell wall. The strain arrays are useful for screening for improved expression of any protein of interest, including therapeutic proteins, hormones, a growth factors, extracellular receptors or ligands, proteases, kinases, blood proteins, chemokines, cytokines, antibodies and the like.
Owner:PFENEX
Lipoproteins as nucleic acid vectors
InactiveUS6635623B1Restores growth suppression controlReduce the numberBiocideApolipeptidesApolipoproteins ELow-density lipoprotein
The present invention relates to materials and methods for the in vivo transport and deliver of nucleic acids. More particularly, it concerns the use of lipoproteins, including but not limited to, low density lipoproteins ("LDL"), and / or apolipoproteins for the binding and in vivo transport of nucleic acids. In addition, the present invention relates to the use of lipoproteins in the early detection of cancer and / or metastatic cancer and / or arteriosclerosis.
Owner:BAYLOR COLLEGE OF MEDICINE
DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER
InactiveUS20050019927A1High efficacyStrong specificityVectorsPeptide/protein ingredientsDecreased ConcentrationIn vivo
Decreasing the expression of genes in a mammalian subject has multiple applications ranging from cancer therapy to anti-infective therapy or treatment of autosomal dominant genetic disorders. Yet, there is still a lack of efficient technologies to achieve that goal in mammalian subjects in vivo. The present invention relates to methods for decreasing gene expression by administering to a mammalian subject a recombinant adeno-associated viral vector in vivo with said vector comprising an RNA interference (RNAi) expression cassette whose RNA expression products directly or indirectly lead to a decrease in expression of the corresponding RNAi target gene. Upon successful transduction with the recombinant adeno-associated viral vector, the RNA expression products of the RNAi expression cassette will decrease the cellular concentration of the mRNA transcripts of the RNAi target gene, thus resulting in decreased concentration of the protein encoded by the RNAi target gene.
Owner:HILDINGER MARKUS +1
Activin-actrii antagonists and uses for increasing red blood cell levels
ActiveUS20090163417A1Reduce expressionIncrease redCompound screeningApoptosis detectionPrimateRed Cell
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Antagonists of activin-actriia and uses for increasing red blood cell levels
ActiveUS20100028331A1Easy to produceReduce expressionPeptide/protein ingredientsAntibody mimetics/scaffoldsPrimateRed Cell
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Activin-ActRIIa antagonists and uses for promoting bone growth
ActiveUS20090098113A1Reduce expressionPromote bone growthPeptide/protein ingredientsAntibody mimetics/scaffoldsIncreased Bone DensityBone growth
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
Owner:ACCELERON PHARMA INC
Activin-ActRIIa antagonists and uses for promoting bone growth
ActiveUS20090099086A1Reduce expressionPromote bone growthPeptide/protein ingredientsAntibody mimetics/scaffoldsIncreased Bone DensityCancer research
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
Owner:ACCELERON PHARMA INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com